Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral extended-release progesterone pharmacokinetic study for postpartum depression biomarker modeling
ACTRN12621001763831Phase 3Withdrawn
- Sponsor
- University of Otago
- Start
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of progesterone in postpartum depression (PPD), sponsored by University of Otago. Primary endpoint: Plasma allopregnanolone concentrations over 0 to 48 hours. Planned start Jan 2022; status: withdrawn.
02
Drugs
progesterone
03
Conditions
postpartum depression (PPD)
Beyond the preview
Go deeper on ACTRN12621001763831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12621001763831.